Why IREN's Post-Market Selloff Misses The Big Picture

分组1 - The article discusses IREN Limited, highlighting that the company's primary business remains focused on Bitcoin mining despite potential shifts in its operations [1] - The author emphasizes the importance of combining scientific expertise with financial analysis to identify promising biotechnology companies that innovate in unique ways [1] - The focus is on evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals [1] 分组2 - The article aims to provide insights that help investors understand both opportunities and risks in the biotechnology sector, which can yield significant returns through breakthrough science [1]